LUCD vs. ICCM, XAIR, CTCX, DXR, CTSO, SEPA, LNSR, DRIO, AMIX, and APYX
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include IceCure Medical (ICCM), Beyond Air (XAIR), Carmell (CTCX), Daxor (DXR), Cytosorbents (CTSO), SEP Acquisition (SEPA), LENSAR (LNSR), DarioHealth (DRIO), Autonomix Medical (AMIX), and Apyx Medical (APYX). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.
Lucid Diagnostics presently has a consensus price target of $2.75, suggesting a potential upside of 205.56%. IceCure Medical has a consensus price target of $2.95, suggesting a potential upside of 180.95%. Given Lucid Diagnostics' higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than IceCure Medical.
IceCure Medical has a net margin of -453.76% compared to Lucid Diagnostics' net margin of -1,576.60%. IceCure Medical's return on equity of -86.96% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
IceCure Medical has higher revenue and earnings than Lucid Diagnostics. IceCure Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, IceCure Medical had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for IceCure Medical and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.19 beat IceCure Medical's score of 0.63 indicating that Lucid Diagnostics is being referred to more favorably in the media.
Lucid Diagnostics received 10 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 94.44% of users gave IceCure Medical an outperform vote while only 61.36% of users gave Lucid Diagnostics an outperform vote.
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Lucid Diagnostics and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
